Skip to main content
. Author manuscript; available in PMC: 2016 May 17.
Published in final edited form as: Vaccine (Auckl). 2016 May 4;6:9–23. doi: 10.2147/VDT.S85545

Table 1. Ft LVS-based live attenuated vaccines.

Vaccine strain (Ft LVS) Growth medium Animal model Sex Vaccine dose (route) Ft LVS challenge % protection (dose, route) Ft SchuS4 challenge % protection (dose, route) References
Ft LVS MHB C57BL/6 F 100 CFU (IN) ND 100% (25 CFU, IN) 131
SodB MHB C57BL/6 M/F 1,200 CFU (IN) 100% (1.2×106 CFU, IN) 40% (103 CFU, IN) 56
ClpB BHI CDM C57BL/6 F 5×104 CFU (IN) 100% (5×103 CFU, IN) 10% (30 CFU, IN) 132
emrA1 MHB C57BL/6 F 106 CFU (IN) 100% (107 CFU, IN) 15% (17 CFU, IN) 87
CapB MHB BALB/c F 106 CFU (IN) ND 100% (10 LD100, aerosol) 133
clpB NA BALB/c NA 5×104 CFU (IN) ND 30% (86 CFU, IN) 134
dsbA McLeod BALB/c F 106 CFU (SC) ND 100% (100 CFU, SC) 50% (100 CFU, IN) 135
wbtA CHAH BALB/c M 1.5×107 CFU (IN) 100% (25 LD, IN) 25% (10 CFU, IN) 136
Wzy MHB BALB/c M 2.4×107 CFU (IN) 100% (1.2×105 CFU, IN) 84% (8 CFU, IN) 137

Abbreviations: Ft, Francisella tularensis; LVS, live vaccine strain; MHB, Mueller Hinton Broth; F, female; ND, not determined; IN, intranasal; M, male; BHI, brain heart infusion; CDM, Chamberlain's defined medium; NA, not available; SC, subcutaneous; CHAH, cysteine heart agar containing 2% hemoglobin; LD50, median lethal dose; LD100, absolute lethal dose.